Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 90

Sort by

Sort Order Select

Journal Articles

Results of Unrelated Donor Hematopoietic Stem Cell Transplantation for Sickle Cell Disease in Europe on Behalf of Paediatric Diseases (PDWP) and Inborn Errors Working Parties (IEWP) of the EBMT

Blood (2019) 134 (Supplement_1): 4583.

https://doi.org/10.1182/blood-2019-121952

Published: 2019

Journal Articles

In-Vivo Adsorption of Iso-Haemagglutinin (IHA) Antibodies By Donor Type Red Cell Transfusion during Conditioning Is a Safe and Effective Method to Overcome Major ABO Incompatibility-Related Acute Hemolytic Reactions in Stem Cell Transplant Using Bone Marrow As Stem Cell Graft Source

Pallavi Mehta, MD DM, Stalin Ramprakash, MD MBBS, C Raghuram, Deepa Trivedi, MD, Priya Marwah, Rajpreet Soni, Rakesh Dhanya, BE, Rajat Kumar Agarwal, BS, Lawrence Faulkner, MD

Blood (2019) 134 (Supplement_1): 4467.

https://doi.org/10.1182/blood-2019-131118

Published: 2019

Journal Articles

Impact of ABO Blood Group Incompatibility on Outcomes after Single-Unit Umbilical Cord Blood Transplantation for Malignant Hematological Disease

Cheng Siqi, Baolin Tang, Xiaoyu Zhu, Huilan Liu, Kaidi Song, Xiang Wan, Wen Yao, Jian Wang, Zimin Sun

Blood (2019) 134 (Supplement_1): 2055.

https://doi.org/10.1182/blood-2019-130699

Published: 2019

Journal Articles

Daratumumab for Delayed Red Cell Engraftment after Hematopoietic Stem Cell Transplant

Claudia I Chapuy, MD, Richard M Kaufman, MD, Edwin P. Alyea, III, MD, Jean M. Connors, BA,MD

Blood (2018) 132 (Supplement 1): 2545.

https://doi.org/10.1182/blood-2018-99-111880

Published: 2018

Journal Articles

Influence of Donor Type, Stem Cell Source and Conditioning Regimen on Transplant Outcomes after Haploidentical Transplant with Post Transplant Cyclophosphamide for Lymphoma: A Report of the EBMT Lymphoma Working Party

Blood (2018) 132 (Supplement 1): 484.

https://doi.org/10.1182/blood-2018-99-111674

Published: 2018

Journal Articles

Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Primary Graft Failure Patients : A Report By the SFGM-TC

Pedro H Prata, MD, Matthieu Resche-Rigon, MD PhD, Didier Blaise, Gérard Socié, MD PhD, Pierre Simon Rohrlich, Noel-Jean Milpied, MD, Pascal Turlure, MD, Stephanie Nguyen, MD PhD, Anne Sirvent, MD, Claude-Eric Bulabois, MD, Eric Deconinck, MD PhD, Amandine Charbonnier, Patrice Chevallier, MD, Jacques-Olivier Bay, MD PhD, Benedicte Neven, MD, Charlotte Jubert, MD, Mohamad Mohty, MD PhD, Marie Thérèse Rubio, MD, Regis Peffault De Latour

Blood (2018) 132 (Supplement 1): 4663.

https://doi.org/10.1182/blood-2018-99-111610

Published: 2018

Journal Articles

Eltrombopag for Prolonged Post-Transplant Hyporigenerative Cytopenias

Luana Marano, Serena Marotta, Fabiana Cacace, Camilla Frieri, MD, Luigia Simeone, Fabio Trastulli, MD, Selenia Vitiello, Flora Cardano, Fabrizio Pane, Antonio M. Risitano, MD PhD

Blood (2018) 132 (Supplement 1): 5711.

https://doi.org/10.1182/blood-2018-99-115381

Published: 2018

Journal Articles

Clinical Outcomes of Matched Unrelated Allogeneic Stem Cell Transplant Patients: Low Dose ATG Vs. No ATG

Luke Mountjoy, DO, Katie L. Kunze, PhD, Tania Jain, MD, James L. Slack, MD, Nandita Khera, MD, Jose F. Leis, MD PhD, Pierre Noel, MD, Lisa Z. Sproat, Jeanne Palmer, MD

Blood (2018) 132 (Supplement 1): 5715.

https://doi.org/10.1182/blood-2018-99-112217

Published: 2018

Journal Articles

Allele-selective RUNX1 binding regulates P1 blood group status by transcriptional control of A4GALT

Julia S. Westman, Linn Stenfelt, Karina Vidovic, Mattias Möller, Åsa Hellberg, Sven Kjellström, Martin L. Olsson

Blood (2018) 131 (14): 1611–1616.

https://doi.org/10.1182/blood-2017-08-803080

Published: 2018

Includes: Supplemental data

Journal Articles

Long-Term Survival in Myelofibrosis after Allogeneic Hematopoietic Cell Transplantation Using Fludarabine/Melphalan Conditioning Regimen

Haris Ali, MD, Ibrahim Aldoss, MD, Dongyun Yang, PhD, Michelle Afkhami, MD, Monzr M. Al Malki, MD, Thai Cao, MD, Stephen J. Forman, MD FACP, Guido Marcucci, MD, Matthew Mei, MD, Sally Mokhtari, PhD, Ryotaro Nakamura, MD, Margaret O'Donnell, MD, Raju Pillai, MD, Vinod Pullarkat, MD MRCP, Amandeep Salhotra, MD, Anthony S. Stein, MD, David S. Snyder, MD

Blood (2017) 130 (Supplement 1): 199.

https://doi.org/10.1182/blood.V130.Suppl_1.199.199

Published: 2017

Journal Articles

Melphalan Dose in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation with Reduced-Intensity Fludarabine and Melphalan

Kaito Harada, MD, Shinichiro Machida, MD, Masamitsu Yanada, MD PhD, Heiwa Kanamori, MD PhD, Makoto Onizuka, MD PhD, Yukiyasu Ozawa, MD PhD, Hikaru Kobayashi, Masashi Sawa, MD, Junya Kanda, MD, Tatsuo Ichinohe, MD PhD, Yoshiko Atsuta, MD PhD, Shingo Yano, MD PhD

Blood (2017) 130 (Supplement 1): 4585.

https://doi.org/10.1182/blood.V130.Suppl_1.4585.4585

Published: 2017

Journal Articles

Transfusion Dependence at Day +100 Predicts Poorer Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation for Myelofibrosis

Tania Jain, MD, Katie L. Kunze, PhD, Daniel K. Partain, MD, Heidi Kosiorek, MS, Vivek Roy, MD, Nandita Khera, MD, James L. Slack, MD, Mrinal M. Patnaik, MDMBBS, William J. Hogan, MBBCh, Pierre Noel, MD, Veena D. S. Fauble, MD, Jose F. Leis, MD PhD, Lisa Sproat, MD MSW, Ruben A Mesa, MD, Jeanne Palmer, MD

Blood (2017) 130 (Supplement 1): 4561.

https://doi.org/10.1182/blood.V130.Suppl_1.4561.4561

Published: 2017

Journal Articles

Fludarabine/Treosulfan/Thiotepa/ATG Conditioning for Related Transplantation in b Thalassaemia Major Leads to Early and Sustained Engraftment with Low Incidence of VOD and GvHD but a High Rate of Long-Term Mixed Chimerism

Farah O'Boyle, PhD, Leena Karnik, FRCPath, MRCP, Kirstin Lund, MRCP, BSc, Richard Szydlo, PhD, Josu de la Fuente, FRCP, PhD FRCPath

Blood (2017) 130 (Supplement 1): 3323.

https://doi.org/10.1182/blood.V130.Suppl_1.3323.3323

Published: 2017

Journal Articles

Fludarabine/Treosulfan/Thiotepa/ATG Conditioning for Related Transplantation in β Thalassaemia Major Leads to Early and Sustained Engraftment with Low Incidence of VOD and GvHD

Farah O'Boyle, PhD, Leena Karnik, MD FRCPath, MBBS,, Anne Bradshaw, Richard M Szydlo, Josu de la Fuente, PhD FRCP, FRCPI, FRCPCH, FRCPath

Blood (2016) 128 (22): 1283.

https://doi.org/10.1182/blood.V128.22.1283.1283

Published: 2016

Journal Articles

Chronic Graft-Versus-Host Disease in Double Cord Blood Transplantation According to National Institutes of Health 2005 Criteria: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party of the EBMT

Hiromi Hayashi, MD, Annalisa Ruggeri, MD, Hanadi Rafii - El Ayoubi, MD, Jan J. Cornelissen, MD PhD, Gerard Socié, MD PhD, Niels S. Andersen, MD PhD, Mauricette Michallet, MD PhD, Dimitrios Karakasis, MD PhD, Eefke Petersen, MD, Joan Hendrik Veelken, MD PhD, Jean Yves Cahn, MD PhD, Pierre-Simon Rohrlich, MD PhD, Melanie Mercier, Fernanda Volt, Chantal Kenzey, Erick Xavier, MD, Vanderson Rocha, MD PhD, Eliane Gluckman, MD PhD

Blood (2016) 128 (22): 3428.

https://doi.org/10.1182/blood.V128.22.3428.3428

Published: 2016

Journal Articles

Impact of ABO Incompatibility on Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation

Oksana Prokopchuk-Gauk, MD FRCPC, Joanna McCarthy, MLT, Peter Duggan, MD FRCPC, Meer-Taher Shabani-Rad, MD FRCPC, Nicole L Prokopishyn, PhD

Blood (2016) 128 (22): 3394.

https://doi.org/10.1182/blood.V128.22.3394.3394

Published: 2016

Journal Articles

Red Cell Alloimmunization Rates in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Oksana Prokopchuk-Gauk, MD FRCPC, Nicole L Prokopishyn, PhD, Joanna McCarthy, MLT, Meer-Taher Shabani-Rad, MD FRCPC

Blood (2016) 128 (22): 3402.

https://doi.org/10.1182/blood.V128.22.3402.3402

Published: 2016

Journal Articles

Hematopoietic Recovery after in-Vivo T-Cell Depleted Allogeneic Stem Cell Transplant- Effects of ABO Incompatibility, Rhesus Incompatibility and Acute Gvhd

Usama Gergis, MD, Naima Ali Al-Mulla, MD MBBS, Segovia Javier, Rania Hafez, MD, Adrienne A. Phillips, MD MPH, Sebastian Mayer, MD, Tsiporah B. Shore, MD, Jing-ming Hsu, MD, Ronit Slotky, PhD, Ljiljana V. Vasovic, MD, Melissa M. Cushing, MD, Koen van Besien, MD

Blood (2016) 128 (22): 5745.

https://doi.org/10.1182/blood.V128.22.5745.5745

Published: 2016

Journal Articles

Evolving Criteria for Donor Selection for Transplants in Acute Myeloid Leukemia

Yu Wang, qi-Fa Liu, de-Pei Wu, Xiao-jun Huang

Blood (2016) 128 (22): 5846.

https://doi.org/10.1182/blood.V128.22.5846.5846

Published: 2016

Journal Articles

First Results of a Prospective Study on Erythropoietin Biosimilar (Epoetin zeta) Use in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Mauricette Michallet, MD PhD, Mohamad Sobh, PharmD, Jeremy Monfray, CRA, Hélène Labussière-wallet, MD, Marie Balsat, MD, Caroline Lejeune, MD, Sophie Ducastelle-Leprêtre, MD, Fiorenza Barraco, MD, Xavier Thomas, Franck E. Nicolini, MD PhD

Blood (2015) 126 (23): 4477.

https://doi.org/10.1182/blood.V126.23.4477.4477

Published: 2015

NARROW

Results of Unrelated Donor Hematopoietic Stem Cell Transplantation for Sickle Cell Disease in Europe on Behalf of Paediatric Diseases (PDWP) and Inborn Errors Working Parties (IEWP) of the EBMT

In-Vivo Adsorption of Iso-Haemagglutinin (IHA) Antibodies By Donor Type Red Cell Transfusion during Conditioning Is a Safe and Effective Method to Overcome Major ABO Incompatibility-Related Acute Hemolytic Reactions in Stem Cell Transplant Using Bone Marrow As Stem Cell Graft Source

Impact of ABO Blood Group Incompatibility on Outcomes after Single-Unit Umbilical Cord Blood Transplantation for Malignant Hematological Disease

Daratumumab for Delayed Red Cell Engraftment after Hematopoietic Stem Cell Transplant

Influence of Donor Type, Stem Cell Source and Conditioning Regimen on Transplant Outcomes after Haploidentical Transplant with Post Transplant Cyclophosphamide for Lymphoma: A Report of the EBMT Lymphoma Working Party

Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Primary Graft Failure Patients : A Report By the SFGM-TC

Eltrombopag for Prolonged Post-Transplant Hyporigenerative Cytopenias

Clinical Outcomes of Matched Unrelated Allogeneic Stem Cell Transplant Patients: Low Dose ATG Vs. No ATG

Allele-selective RUNX1 binding regulates P1 blood group status by transcriptional control of A4GALT

Long-Term Survival in Myelofibrosis after Allogeneic Hematopoietic Cell Transplantation Using Fludarabine/Melphalan Conditioning Regimen

Melphalan Dose in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation with Reduced-Intensity Fludarabine and Melphalan

Transfusion Dependence at Day +100 Predicts Poorer Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation for Myelofibrosis

Fludarabine/Treosulfan/Thiotepa/ATG Conditioning for Related Transplantation in b Thalassaemia Major Leads to Early and Sustained Engraftment with Low Incidence of VOD and GvHD but a High Rate of Long-Term Mixed Chimerism

Fludarabine/Treosulfan/Thiotepa/ATG Conditioning for Related Transplantation in β Thalassaemia Major Leads to Early and Sustained Engraftment with Low Incidence of VOD and GvHD

Chronic Graft-Versus-Host Disease in Double Cord Blood Transplantation According to National Institutes of Health 2005 Criteria: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party of the EBMT

Impact of ABO Incompatibility on Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation

Red Cell Alloimmunization Rates in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Hematopoietic Recovery after in-Vivo T-Cell Depleted Allogeneic Stem Cell Transplant- Effects of ABO Incompatibility, Rhesus Incompatibility and Acute Gvhd

Evolving Criteria for Donor Selection for Transplants in Acute Myeloid Leukemia

First Results of a Prospective Study on Erythropoietin Biosimilar (Epoetin zeta) Use in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only